Zika virus infection in pregnancy: a systematic review of
                disease course and complications by Chibueze, Ezinne C. et al.
Chibueze et al. Reproductive Health  (2017) 14:28 
DOI 10.1186/s12978-017-0285-6REVIEW Open AccessZika virus infection in pregnancy: a
systematic review of disease course
and complications
Ezinne C. Chibueze1*†, Veronika Tirado2†, Katharina da Silva Lopes1, Olukunmi O. Balogun1, Yo Takemoto1,
Toshiyuki Swa1,3, Amarjargal Dagvadorj1,4, Chie Nagata5, Naho Morisaki6, Clara Menendez7,8, Erika Ota1,9,
Rintaro Mori1 and Olufemi T. Oladapo8Abstract
Objectives: To characterize maternal Zika virus (ZIKV) infection and complement the evidence base for the WHO
interim guidance on pregnancy management in the context of ZIKV infection.
Methods: We searched the relevant database from inception until March 2016. Two review authors independently
screened and assessed full texts of eligible reports and extracted data from relevant studies. The quality of studies
was assessed using the Newcastle-Ottawa Scale (NOS) and the National Institute of Health (NIH) tool for observational
studies and case series/reports, respectively.
Results: Among 142 eligible full-text articles, 18 met the inclusion criteria (13 case series/reports and five
cohort studies). Common symptoms among pregnant women with suspected/confirmed ZIKV infection were
fever, rash, and arthralgia. One case of Guillain-Barré syndrome was reported among ZIKV-infected mothers,
no other case of severe maternal morbidity or mortality reported. Complications reported in association with
maternal ZIKV infection included a broad range of fetal and newborn neurological and ocular abnormalities;
fetal growth restriction, stillbirth, and perinatal death. Microcephaly was the primary neurological complication
reported in eight studies, with an incidence of about 1% among newborns of ZIKV infected women in one
study.
Conclusion: Given the extensive and variable fetal and newborn presentations/complications associated with
prenatal ZIKV infection, and the dearth of information provided, knowledge gaps are evident. Further research
and comprehensive reporting may provide a better understanding of ZIKV infection in pregnancy and attendant
maternal/fetal complications. This knowledge could inform the creation of effective and evidence-based strategies,
guidelines and recommendations aimed at the management of maternal ZIKV infection. Adherence to current best
practice guidelines for prenatal care among health providers is encouraged, in the context of maternal ZIKV infection.Plain english summary
Aedes mosquitoes transmit Zika virus (ZIKV) infection,
its clinical presentation in humans is often mild or
asymptomatic. Due to a marked increase in the number
of symptomatic or suspected cases across continents,
ZIKV infection was declared a Public Health Emergency
of International Concern (PHEIC) on February 1, 2016.* Correspondence: ezinne.chibueze@gmail.com
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(http://creativecommons.org/publicdomain/zePregnant women are at an exceptional risk of being
affected with potential adverse effects. To describe ma-
ternal Zika virus (ZIKV) infection and complement the
evidence base for the WHO interim guidance on preg-
nancy management and in the context of ZIKV infec-
tion, we did a systematic review.
We conducted database searches, independent screen-
ing of records and assessment of resulting full texts from
which we extracted data. We further assessed the quality
of the included studies.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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from the 18 studies which met the inclusion criteria (13
case series/reports and five cohort studies). Among the
pregnant women with suspected/confirmed ZIKV infec-
tion in these studies, fever, rash and joint-pain were the
commonly reported symptoms. Neurological affectation
(Guillain-Barre syndrome) was reported in one mother,
no other cases of severe maternal illness or deaths were
reported. Complications reported in association with
maternal ZIKV infection included a broad range of fetal
and newborn neurological and ocular abnormalities;
fetal growth restriction, stillbirth, and perinatal death.
Microcephaly was the primary neurological complica-
tion reported in eight studies, with an incidence of
about 1% in one study.
In conclusion, knowledge gaps on the features charac-
terising maternal ZIKV infection and its effects are evi-
dent. Further research and better reporting practices
may help create effective strategies aimed at the manage-
ment of maternal ZIKV infection and subsequent fetal
complications. Pregnant women and health providers
are encouraged to adhere to current best practice guide-
lines, in the context of maternal ZIKV infection.
Background
Since the late 1940s, there have been reports of Zika
virus (ZIKV) isolated from rhesus monkeys in Uganda,
and human cases in Tanzania and Nigeria [1, 2]. At
present, ZIKV has a broad distribution across sub-
Saharan Africa, South-East Asia, and the Americas [3].
ZIKV belongs to the Flaviviridae family of viruses and is
transmitted by Aedes mosquitoes.
In humans, ZIKV infection is often mild or asymptom-
atic. However, an exponential increase in the number of
symptomatic or suspected cases across continents has
intensified international concern [4]. Prior to 2007, few
cases of ZIKV infection were reported [5]. Thereafter, an
infectious outbreak affecting 74.6% of the Micronesian
Yap population [6] and 32,000 people in the French
Polynesian region in 2013–2014 were reported [7, 8]. In the
latest outbreak in 2015, up to 1.3 million suspected cases
were identified in Brazil over a 9-month period [9, 10]. In
addition to transmission by Aedesmosquitoes, sexual trans-
mission has also been reported [11, 12].
Despite the international efforts to curb its spread, ZIKV
infection has expanded to 62 countries and territories, and
is projected to increase due to potential climate change
affecting the spread of the ZIKV Aedes vector [7, 13–15].
Notably in 2015, a 20-fold increase in the incidence of
microcephaly relative to previous years was reported with
the onset of ZIKV transmission in northeastern Brazil.
This trend led to the World Health Organization (WHO)
declaring a Public Health Emergency of International
Concern (PHEIC) on February 1, 2016 [13, 16, 17].Pregnant women are at exceptional risk of being in-
fected with ZIKV infection and exhibiting potential ad-
verse effects, including a wide range of congenital
abnormalities associated with ZIKV infection in utero.
Delayed or arrested neurological development and com-
plications common in fetuses and neonates born to
ZIKV-infected women, may drain family resources due
to the need for special care. Perinatal deaths may further
impose an emotional burden on affected families. The
health systems in most ZIKV-affected areas have limited
resources to manage the current outbreak and its
consequences.
Many gaps in the knowledge regarding ZIKV infection
exist, these include, the clinical spectrum of disease
presentation in infected pregnant women, mechanisms
of vertical transmission, and the risk of complications in
mother, fetus and newborn. Also, the impact of ZIKV
co-infection with other flaviviruses on pregnancy as well
as the long-term consequence of ZIKV infection among
infants and adults of reproductive age is unclear. As part
of the process to complement the evidence base for
WHO interim guidance on pregnancy care in the con-
text of ZIKV infection and close the knowledge gaps, we
conducted a systematic review.
Methods
Search strategy
We searched the following electronic databases: MED-
LINE, EMBASE, CINAHL, World Health Organization
Global Health Library (WHOGL), and Cochrane Central
Register of Controlled Trials (CENTRAL) on March 3,
2016. An information specialist configured search terms
for each database according to the level of term index-
ation. Search terms included flavivirus, chikungunya
virus, fever, arbovirus, Zika, congenital malformations,
cephalometry, and nervous system abnormalities as
shown in Additional file 1). There were no dates, lan-
guage or study design restrictions. We registered this re-
view in PROSPERO, the international prospective
register of systematic reviews of the University of York
and the National Institute for Health Research, under
the number CRD4201603969.
Selection of studies
We considered all study designs including randomized
controlled trials, prospective or retrospective cohorts,
cross-sectional, case-control studies and case series/re-
ports. Original reports, briefs, letters, editorials, corres-
pondence and news reports were considered for
inclusion. A minimum of two review authors assessed
the title and abstract of references for relevance to re-
view objectives. We evaluated the full text of potentially
eligible records for inclusion relative to our review ob-
jectives. The review objectives included primary data on
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and their babies and the risk of adverse pregnancy out-
comes. References of included reports were also searched
for potentially eligible studies. Disagreements on the eligi-
bility of reports, where present, were resolved by consen-
sus with a third review author.
Types of studies
We included all studies reporting on ZIKV infection and
complications in pregnant women residing in or with a
history of travel to areas of ongoing ZIKV transmission
or recent ZIKV outbreaks. Studies comparing pregnant
and non-pregnant women with ZIKV infection were
considered for inclusion where available. We excluded
any study or report on non-pregnant populations or
lacking primary data.
Types of participants
Pregnant women suspected of being at risk of, or diag-
nosed with ZIKV infection regardless of their location,
or who have had sexual contact with a partner who (i)
recently returned from an area of active ZIKV transmis-
sion, or (ii) was diagnosed with ZIKV infection.
Data extraction and synthesis
Two review authors independently extracted and pre-
sented data based on the review objectives in an agreed
data collection form. We summarized the data in a
descriptive form (Table 1).
We extracted information on study design, sample size,
history of maternal and fetal ZIKV infection, symptoms,
presence and type of clinical features, pregnancy-specific
complications during pregnancy, childbirth or postpartum
period. The absolute risk of microcephaly and other birth
defects was also recorded where available.
Risk of bias assessment
Two review authors conducted independent assessments
on the quality of included studies. Where discordance in
ranking was observed, this was resolved by consensus or
discussion with a third review author. For individual case
series/reports, a quality assessment of the National Insti-
tute of Health Tool (NIH) [18] was applied. This tool in-
cludes questions based on nine criteria to which either
of the binary answers (Yes/No) was allotted. Based on
the number of ‘Yes’ answers, a rating of good (7 – 9),
fair (4 – 6) or poor (≤3) was allocated to the individual
study and differences in quality ratings amended by con-
sensus. Studies for which the criteria were irrelevant
were labelled ‘not applicable’ and ‘cannot determine’ if
such information was lacking in the study.
For observational studies, we applied the Newcastle-
Ottawa Scale [18] which consisted of lead questions aimed
at assessing three domains – selection, comparability, andoutcome. For each outcome, a maximum of three points
could be allotted as previously described [20].
Results
Search results
Search strategies identified 2316 records as shown in the
PRISMA flow chart in Fig. 1. Based on the title and ab-
stract screening, 2174 records were excluded due to lack
of primary data and/or irrelevance to review objective.
Of the resulting 142 eligible full texts, 18 studies met
our inclusion criteria (reasons for exclusion are outlined
in Additional file 2).
Characteristics of included studies
All but one study were published in 2016 [21]. The stud-
ies were conducted largely in South America: Brazil [11],
Colombia [1], Puerto Rico [1], and Venezuela [1]. Other
studies were conducted in France [1], Slovenia [1] and
the USA [2]. In all studies, pregnant women were either
living in areas of ongoing transmission [21–35], had re-
sided in [36], or travelled [37] to ZIKV-affected areas
during pregnancy.
Regarding study design, there were 13 case series/re-
ports [21, 23–27, 28, 30, 32, 34–35] and five observational
studies [22, 26, 29, 31, 33]. The observational studies were
either prospective [33], retrospective [22] or mixed [29,
31] in design. All presented information on clinical mani-
festations, pregnancy-specific complications and diagnoses
in women and their fetuses/newborns.
Diagnostic tests to confirm the presence of ZIKV infec-
tion in pregnant women included reverse transcription
polymerase chain reaction (RT-PCR) for ZIKV nucleic ma-
terial [21, 25, 29, 30, 33, 35, 37] and tests on serum [21, 24],
breastmilk [21], amniotic fluid [37] and urine [24] samples.
IgG and IgM antibody tests for viral ZIKV exposure were
also conducted [24, 28, 33, 35]. Eleven of the 18 included
studies conducted serological tests to exclude other infec-
tions such as dengue [21, 27, 32, 33], chikungunya [32],
toxoplasmosis [22, 24, 27, 28, 32, 34], rubella [22–24, 27,
28, 32, 33], cytomegalovirus [22–24, 27, 28, 32, 33], herpes
simplex virus [22, 24, 27, 28, 32], HIV [22, 24, 27, 28, 32,
35], Human T-cell lymphotrophic virus [35], Hepatitis C
Virus [35] and Hepatitis B Virus [24].
For fetal imaging, ultrasound [24, 30, 32, 35], com-
puted tomography scanning for brain calcifications [25]
and magnetic resonance imaging [37] were employed.
In some studies, ocular examinations were also con-
ducted for the mother [34] and newborn [22, 34].
Characteristics of maternal ZIKV infection
Symptoms/signs/complications
No study suggested a higher risk of acquiring ZIKV infec-
tion in pregnant women compared to the non-pregnant
population, after exposure to Aedes mosquitoes. Most
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Fig. 1 Flow diagram of search results and study selection
Chibueze et al. Reproductive Health  (2017) 14:28 Page 7 of 14studies only presented fetal and newborn features without
further information on how these varied with the gesta-
tional age at the time of maternal ZIKV infection.
Rash was the most common sign of ZIKV infection
in pregnant women in 15 of 18 included reports
[21–29, 32–34]. Two of the remaining three studies
(one observational study, one case series) did not re-
port clinical manifestations during pregnancy as they
focused on the newborns of ZIKV-infected mothers
[30, 31]. Rash was absent in the third study as the
mothers were asymptomatic [35]. In seven reports, the
rash was further qualified as ‘a pruritic cutaneous rash with
itching in the back and hands’, ‘generalised, descending
macular’ or ‘generalised maculopapular’ [21, 28, 33],
‘petechial’ or ‘generalised’ [21, 28, 32, 33, 36]. Only one
case-series reported on symptom occurrence after delivery
in two ZIKV-infected pregnant women [21]. A 4-dayduration of persistent rash in one pregnant woman and
a pruritic rash on the third day after childbirth in the
second case was observed. In the former, the rash
started 2 days before and ended 2 days after delivery of
a healthy infant. In the latter case, a mild fever and my-
algia were also reported.
Other reported signs and symptoms included fever
[22–24, 27–29, 32, 33], chills [23, 24], malaise [24,
29, 34], arthralgia [22, 24, 28, 29, 33, 34], myalgia
[23, 24, 29, 32, 33], myotonia [23], asthenia [24],
jaundice [24], paraesthesia [33], hemiparesis [24],
headache [22, 28], conjunctivitis or conjunctival in-
jections [23, 33], lymphadenopathy [33], pain (eye,
abdominal, lumbar, pelvis, body and joint) [24, 29],
anaemia [24], edema in lower limbs [24], nausea [25,
33], vomiting [33], dermal bleeding [33] and ‘respira-
tory findings’ [33].
Chibueze et al. Reproductive Health  (2017) 14:28 Page 8 of 14The grade of fever was provided in three reports, a low
grade fever of 37.5 to 38.0 °C in two reports [21, 33] and a
“high fever” [36] in the third. Fever was absent in ZIKV-
infected pregnant women in two case reports [35].
An observational study reported a significantly higher
frequency of lymphadenopathy and conjunctival injections
in ZIKV-infected compared with uninfected pregnant
women [33].
Twelve studies provided information on trimester-
specific occurrence of symptoms [21, 23, 24, 26–29, 32,
34]. Symptoms were observed more commonly in the
first trimester [24, 26–28, 32, 34]. Among the ZIKV-
infected pregnant women in individual reports, seven
studies reported no signs or symptoms [22, 24, 26, 28,
34, 35].
Neurological complications were reported in ZIKV-
infected pregnant women in one case report [23] and
one observational study [33]. Guillain-Barré syndrome
(GBS) at 28 weeks gestation in addition to other typical
ZIKV signs and symptoms were reported in one case re-
port only [23]. The patient had respiratory distress that
prompted intensive care unit (ICU) admission. She fully
recovered within 3 weeks and gave birth to a normal in-
fant at 39 weeks of gestation.
Preterm birth necessitating emergency caesarean deliv-
ery was reported in two observational studies [27, 33]
and one case series [21]. In the two observational stud-
ies, intrauterine growth restriction (IUGR) was an
underlying complication. In one of the studies [33], the
two preterm births reported were due to IUGR accom-
panied by oligohydramnios, macular hypoplasia, and pla-
cental insufficiency in one fetus and anhydramnios in
the other.
Miscarriages were reported in five ZIKV-infected preg-
nant women in two case series [27] and one observa-
tional study [33]. Stillbirths were also recorded in three
pregnant women in one observational study and one
case report [33, 35].
Characteristics of fetuses/newborns of ZIKV infected
pregnant women
Fetuses
Complications A wide spectrum of complications was
reported in association with maternal ZIKV infection
(Table 2). Microcephaly visible on fetal ultrasound was
the main neurologic complication in two observational
studies and six case series/reports [24, 27, 29, 30, 32, 33,
35]. Among them, ocular abnormalities [22, 28, 30, 32,
34], cerebral calcifications and cerebellar abnormalities
were commonly reported [24, 30, 32–35]. In one
observational study of 35 infants with microcephaly [26],
11 fetuses had intra-uterine brain injury accompanied by
stunting of cerebral growth prior to birth. Cerebralabnormalities included brain atrophy, absent corpus cal-
losum, and ventriculomegaly.
Ocular abnormalities included intraocular calcifications
and microphthalmia [30, 32].
In fetuses of ZIKV-infected pregnant women, placental
and umbilical [32, 33] and amniotic fluid [33] abnormal-
ities were reported.
IUGR was reported in five studies (two observational,
three case-series/reports) [21, 33] and stillbirths in two
studies [33, 35]. Despite normal fetal biometrics at
14 weeks in one case of an asymptomatic ZIKV-infected
pregnant woman, IUGR was detected at 18 weeks and
accompanied by other neurological abnormalities includ-
ing microcephaly, hydranencephaly, hydrops fetalis and
eventual stillbirth [35].
Fetal deaths were reported in two studies (one case
series and one observational study), these deaths oc-
curred in four fetuses at > 30 weeks gestation [27, 33].
Elective terminations of pregnancies were conducted for
seven pregnant women. However, the gestational age or
trimester of termination was unknown [31].
Newborns
Symptoms/signs Rash described as ‘transient isolated
diffuse’ was reported in an infant on the fourth day post-
delivery [21]. Other symptoms reported included con-
junctivitis or conjunctival injections [24, 28].
Complications Similar to fetuses, microcephaly was ob-
served at birth in 11 studies (four observreports)/reports)
[22, 26–30, 32–34] with accompanying ocular and brain
abnormalities. In four studies, microcephaly that was ob-
served at birth was preceded by a fetal diagnosis of IUGR
[25, 32, 34, 35]. Ocular abnormalities included focal
pigment mottling, chorioretinal macular atrophy, optic
nerve abnormalities, cataracts, intra-ocular calcifications,
microphthalmia, conjunctival injections, optic disc cup-
ping, lens subluxation in addition to bilateral iris colo-
boma, foveal reflex loss, macular hypoplasia and scarring
[22, 28, 34, 38].
Musculoskeletal abnormalities reported included clubfoot
[33] and severe arthrogryposis [30, 32] in two case series.
In one case report, ‘arthrogryposis’ was also reported at
post-mortem examination [35].
Four studies reported the birth of healthy infants
[23, 33, 37] and one study reported early neonatal
deaths in three infants with microcephaly within 20 h
of delivery [27].
Absolute risk of fetal microcephaly (and other birth defects)
in women with ZIKV infection
No report provided detailed information from which fac-
tors related to ZIKV infection could be described. One
Ta
b
le
2
M
et
ho
do
lo
gi
ca
lq
ua
lit
y
as
se
ss
m
en
t
fo
r
ca
se
re
po
rt
s
us
in
g
th
e
N
at
io
na
lI
ns
tit
ut
e
St
ud
y
ID
Ve
nt
ur
a
C
.V
[3
4,
38
]
Ve
nt
ur
a
C
.V
[3
4,
38
]
Sa
rn
o
M
[3
5]
Vi
lla
m
il
G
om
ez
W
.E
[2
4]
Th
om
as
D
.L
[2
5]
Re
yn
a-
Vi
lla
sm
il
[2
3]
O
liv
ei
ra
M
el
o
[3
0]
M
la
ka
r
[3
6]
M
ea
ne
y-
D
el
m
an
[3
7]
C
al
ve
t
G
[3
2]
Br
as
il
M
ar
tin
es
[2
7]
Be
sn
ar
d
M
[2
1]
de
Pa
ul
a
Fr
ei
ta
s
[2
8]
1.
W
as
th
e
st
ud
y
qu
es
tio
n
or
ob
je
ct
iv
e
cl
ea
rly
st
at
ed
?
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
N
O
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
2.
W
as
th
e
st
ud
y
po
pu
la
tio
n
cl
ea
rly
an
d
fu
lly
de
sc
rib
ed
,i
nc
lu
di
ng
a
ca
se
de
fin
iti
on
?
N
O
YE
S
YE
S
YE
S
N
O
YE
S
N
O
YE
S
YE
S
YE
S
N
O
YE
S
YE
S
3.
W
er
e
th
e
ca
se
s
co
ns
ec
ut
iv
e?
YE
S
YE
S
N
A
YE
S
N
O
N
A
YE
S
N
A
YE
S
YE
S
YE
S
YE
S
YE
S
4.
W
er
e
th
e
su
bj
ec
ts
co
m
pa
ra
bl
e?
YE
S
YE
S
N
A
YE
S
N
O
N
A
YE
S
N
A
YE
S
YE
S
YE
S
YE
S
YE
S
5.
W
as
th
e
ex
po
su
re
cl
ea
rly
de
sc
rib
ed
?
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
N
O
YE
S
YE
S
6.
W
er
e
th
e
ou
tc
om
e
m
ea
su
re
s
cl
ea
rly
de
fin
ed
,v
al
id
,r
el
ia
bl
e,
an
d
im
pl
em
en
te
d
co
ns
ist
en
tly
ac
ro
ss
al
ls
tu
dy
pa
rt
ic
ip
an
ts
?
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
YE
S
N
O
7.
W
as
th
e
le
ng
th
of
fo
llo
w
-u
p
ad
eq
ua
te
?
N
O
YE
S
YE
S
YE
S
a C
D
YE
S
a C
D
YE
S
a C
D
YE
S
N
O
N
O
N
A
8.
W
er
e
th
e
st
at
ist
ic
al
m
et
ho
ds
w
el
l-
de
sc
rib
ed
?
N
O
YE
S
N
O
N
O
N
O
N
O
b
N
A
N
O
b
N
A
b
N
A
b
N
A
b
N
A
YE
S
9.
W
er
e
th
e
re
su
lts
w
el
l-d
es
cr
ib
ed
?
YE
S
YE
S
YE
S
YE
S
N
O
YE
S
YE
S
YE
S
N
O
YE
S
YE
S
YE
S
YE
S
Q
ua
lit
y
Ra
tin
g
(G
oo
d,
Fa
ir,
or
Po
or
)
FA
IR
G
O
O
D
G
O
O
D
G
O
O
D
Le
tt
er
to
ed
ito
r
PO
O
R
Se
le
ct
iv
e
re
po
rt
in
g
G
O
O
D
Le
tt
er
to
ed
ito
r
FA
IR
G
O
O
D
FA
IR
G
O
O
D
FA
IR
G
O
O
D
G
O
O
D
a C
D
ca
nn
ot
de
te
rm
in
e
b
N
A
N
ot
av
ai
la
bl
e
Chibueze et al. Reproductive Health  (2017) 14:28 Page 9 of 14
Chibueze et al. Reproductive Health  (2017) 14:28 Page 10 of 14observational study provided a trimester-specific model-
ling estimate risk for microcephaly in first [95 cases
(95% confidence interval (CI) 34-191)], second [84 cases
(95% CI 12–196)] and third [0 case (95% CI 0–251)] tri-
mesters, per 10,000 ZIKV-infected pregnant women
[30]. The baseline prevalence for the risk of microceph-
aly were 2% (0 – 8), corresponding to a risk ratio of 53.4
(95% CI 6.5 – 1061.2) in the first trimester; 4% (95% CI
0 – 12), corresponding to a risk ratio of 23.2 (95% CI 1.4
– 407.8) in the second trimester; and 10% (95% CI 3 –
18), corresponding to a risk ratio of 0 (95% CI 0 – 49.3)
in the third trimester.
Fetal abnormalities, including microcephaly, were de-
tected in women who underwent an ultrasound at time-
points ranging between 26 and 30 weeks [30, 35, 36].
Impact of ZIKV co-infection in pregnancy
There was a lack of information on co-infection with
other flaviviruses and common congenital infections in
some studies. Serological tests were conducted in studies
to exclude possible co-infections and/or antibody tests
for previous exposure to other related flaviviruses.
Eleven reports assessed for the presence of co-
infections, toxoplasmosis [22, 24, 27, 28, 32–35, 38],
dengue [21, 27, 32], chikungunya [27, 32], HIV [22, 24,
27, 28, 32, 33, 35, 38], hepatitis B virus (HBV) [24],
hepatitis C virus (HCV) [35], cytomegalovirus (CMV)
[22, 24, 27, 28, 32, 33, 35, 38], herpes simplex virus
(HSV) [22, 24, 27, 28, 32, 38], Epstein-Barr virus (EBV)
[24], rubella [22, 24, 27, 28, 32, 33, 35, 38], human T
lymphotrophic virus (HTLV) [35], parvovirus B19 [32],
syphilis [24, 28, 32] and rheumatoid fever [24].
Four reports assessed previous exposure to other in-
fections based on the presence of IgG [24, 28, 33, 35]
and IgM [28, 35] antibody positivity to cytomegalovirus,
rubella and toxoplasmosis [24, 33, 35] infections. IgG
positivity to infections indicating exposure to dengue
virus in 88% of 88 pregnant women was reported in one
observational study [33], and toxoplasmosis and rubella
in three of 28 women [24] in two case series/report.
Risk of bias assessment
We judged the overall risk of bias as fair or good for all
the included case series/reports except one, which we
rated as poor [25] due to selective reporting (Table 2).
Four of five observational studies included in the re-
view were assigned an average quality rating of four to
five stars based on the NOS. One observational study
[22] was assigned a very low quality rating of one star as
it provided sparse information (Table 3).
Discussion
Our systematic review describes the complications to
fetuses and newborns have been reported during ZIKVinfection in pregnant women. However, no study clearly
described the history of maternal ZIKV infection and its
effects on newborns of affected mothers. A lack of infor-
mation on factors related to ZIKV infection in preg-
nancy further limits our understanding. Most studies
were conducted in 2016, these studies focused on the
presenting symptoms and associated complications in
pregnant women and their fetuses/newborns. Relative to
non-pregnant women or the general population [12, 39],
symptoms and complications of ZIKV infection were
comparable.
Maternal ZIKV infection tended to have more adverse
effects on the fetus and the infant than on the mother,
as most maternal symptoms were self-limiting. A broad
spectrum of clinical presentation was observed in fetuses
and newborns of ZIKV-infected mothers, ranging from
normal to abnormal ultrasound findings during preg-
nancy, such as healthy newborns or newborns with an
abnormality. A similar pattern was observed in ZIKV-
infected pregnant women, ranging from symptomatic
and asymptomatic clinical presentation to uncompli-
cated deliveries in most studies. Severe pregnancy-
specific complications were uncommon and no maternal
deaths were recorded. This highlights a challenge for
both health providers and mothers at risk because of the
increased likelihood of missed opportunities due to the
frequent asymptomatic presentation.
The diagnostic accuracy of tests employed in the ZIKV
context is still unclear [40] because existing studies are
based on epidemiological models. In some women, ZIKV
positivity was confirmed later in pregnancy, although the
standard RT-PCR tests done in early trimesters were
negative. Fetal ultrasound tests that were negative in the
first and second trimesters were positive in late preg-
nancy stage [35]. The absolute risk of developing fetal
abnormalities is also unclear, but microcephaly is un-
likely being a rare condition.
ZIKV shares the same vector with other arboviruses
including chikungunya and dengue. TORCH (Toxoplas-
mosis, Other (syphilis, varicella-zoster, parvovirus B19),
Rubella, Cytomegalovirus (CMV), and Herpes) infections
have been associated with congenital malformations
including central nervous system anomalies. In the in-
cluded reports, the absence of co-infection with or pre-
vious exposure to other viruses was established in most
of the pregnant women. In some studies, IgG-positivity
to dengue and toxoplasma were observed. Immunity to
rubella and CMV were reported in some women with
poor outcomes. Potential synergy due to the presence of
immunity and/or seropositivity to other viruses could
not be ascertained as clinical presentation varied from
the absence of symptoms to the presence of typical
symptoms seen in ZIKV-infected pregnant women. In
one study, about half of the pregnant women who
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Chibueze et al. Reproductive Health  (2017) 14:28 Page 13 of 14presented with rash had lymphadenopathy [33], a condi-
tion commonly observed in dengue infection due to
lymphatic infiltration [41]. Although inconclusive, the his-
tory of lymphadenopathy in some pregnant women in this
study in addition to the presentation of rash may show a
possible role for dengue in extending the spectrum of ma-
ternal or fetal presentation. Indirect evidence from the
history of viral infections that share similar characteristics
and complications with ZIKV, such as CMV, may be im-
portant in understanding ZIKV infection.
In some studies, sample selection was based on the
presenting clinical features. Limitation of the study
population to only pregnant women presenting with fea-
tures suggestive of ZIKV infection such as rash and fe-
tuses with microcephaly as seen in some reports could
be misleading. The rigorous search strategy, the inclu-
sion of foreign language studies and exclusion of over-
lapping studies add to the strength of this review.
The broad spectrum of clinical presentation and compli-
cations in fetuses and newborns of ZIKV-infected pregnant
women provides an insight into the potential liability for
affected women, their families and health systems in
resource-constrained settings. The possibility of an asymp-
tomatic presentation proposes an emphasis on routine
antenatal care and attention to signs of fetal brain abnor-
malities by health providers in pregnant women with
molecular or epidemiological links to ZIKV infection.
Ongoing research on live animal models may help to
understand the pathogenesis of ZIKV, with a potential
for application to exposed pregnant cohorts. The rapid
rate of emerging data from research on Zika virus infec-
tions in pregnancy and recent years proposes a need for
frequent updates. As newer studies become available,
further research on adverse pregnancy outcomes and
implications on long-term consequences of ZIKV during
pregnancy will further enable early diagnosis and better
management modalities in provider care. Furthermore,
personal protective measures should be encouraged.
Conclusions
This review highlights key evidence gaps that need to be
urgently prioritized by the international community,
more so, with the wide variations in fetal and newborn
presentations/complications associated with prenatal
ZIKV infection. Further research and comprehensive
reporting of maternal ZIKV infection and fetal/neonatal
complications may provide a better understanding of
ZIKV infection in pregnancy and its attendant maternal/
fetal complications. Such knowledge could inform the cre-
ation of effective and evidence-based strategies, guidelines,
recommendations and health policies aimed at the man-
agement of maternal ZIKV infection.
Adherence to current best practices guidelines for pre-
natal care among health providers is encouraged. Theseinclude appropriate notification of suspected cases to
the responsible authorities, long-term evaluation, moni-
toring and follow-up for newborns and infants exposed
to ZIKV infection by a multidisciplinary team of health
providers, more so, with ongoing variations in presenta-
tion and distribution of maternal ZIKV infection.
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